Cell Rep:新研究发现促进小细胞肺癌发生发展和转移的重要分子

2016-07-10 佚名 生物谷

近日,来自荷兰癌症研究所的科研人员在国际学术期刊Cell Reports上发表了一项最新研究进展,他们在小细胞肺癌小鼠模型上找到了一种促进肿瘤发生和发展的重要转录因子,并且也在人类肿瘤样本中对该分子的表达情况与肿瘤进展之间的相关性进行了验证。该研究或为小细胞肺癌治疗和疾病进展诊断提供新的靶点和诊断标记。 小细胞肺癌(SCLC)是一种恶性的神经内分泌肿瘤,目前还没有文献报道找到有效的治疗


近日,来自荷兰癌症研究所的科研人员在国际学术期刊Cell Reports上发表了一项最新研究进展,他们在小细胞肺癌小鼠模型上找到了一种促进肿瘤发生和发展的重要转录因子,并且也在人类肿瘤样本中对该分子的表达情况与肿瘤进展之间的相关性进行了验证。该研究或为小细胞肺癌治疗和疾病进展诊断提供新的靶点和诊断标记。

小细胞肺癌(SCLC)是一种恶性的神经内分泌肿瘤,目前还没有文献报道找到有效的治疗方法。该研究团队在之前研究中通过抑制Rb1和Trp53表达建立了SCLC小鼠模型,他们发现该小鼠经常出现Nfib和Mycl基因的异常表达。

在这项研究中,研究人员报告称虽然过表达上述任意一种转录因子都能够促进肿瘤生长,但是NFIB能够特异性的促进肿瘤的转移扩散。NFIB高表达水平与分化程度较低并且呈E-cadherin(CDH1)阴性的侵袭性肿瘤细胞群体的扩张性生长具有相关性。

与小鼠的研究数据一致,研究人员发现NFIB在几乎所有检测过的人类转移性高级别神经内分泌肺部肿瘤中都存在过表达,这提示NFIB或可成为临床检测肿瘤进展的一个标记物。

之前一些研究已经发现NFIB作为癌基因在三阴性乳腺癌,食管鳞状细胞癌以及下颌下腺癌等疾病中存在过表达,该研究进一步在小细胞肺癌中对NFIB的促癌作用进行了证明。这些结果都表明NFIB可能是癌症治疗和诊断的一个潜在靶点。 

原始出处

Ekaterina A. Semenova1, 10, Min-chul Kwon1, 10, Kim Monkhorst2, 10.Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.Cell Rep.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753147, encodeId=17761e5314740, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Jun 25 10:03:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814766, encodeId=333c1814e6676, content=<a href='/topic/show?id=479d96059ae' target=_blank style='color:#2F92EE;'>#重要分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96059, encryptionId=479d96059ae, topicName=重要分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Apr 15 23:03:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959713, encodeId=e7621959e13b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 10 03:03:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030720, encodeId=854e2030e20af, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Mar 03 23:03:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869455, encodeId=1d841869455db, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 13 00:03:00 CST 2017, time=2017-01-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1753147, encodeId=17761e5314740, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Jun 25 10:03:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814766, encodeId=333c1814e6676, content=<a href='/topic/show?id=479d96059ae' target=_blank style='color:#2F92EE;'>#重要分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96059, encryptionId=479d96059ae, topicName=重要分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Apr 15 23:03:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959713, encodeId=e7621959e13b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 10 03:03:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030720, encodeId=854e2030e20af, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Mar 03 23:03:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869455, encodeId=1d841869455db, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 13 00:03:00 CST 2017, time=2017-01-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1753147, encodeId=17761e5314740, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Jun 25 10:03:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814766, encodeId=333c1814e6676, content=<a href='/topic/show?id=479d96059ae' target=_blank style='color:#2F92EE;'>#重要分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96059, encryptionId=479d96059ae, topicName=重要分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Apr 15 23:03:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959713, encodeId=e7621959e13b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 10 03:03:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030720, encodeId=854e2030e20af, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Mar 03 23:03:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869455, encodeId=1d841869455db, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 13 00:03:00 CST 2017, time=2017-01-13, status=1, ipAttribution=)]
    2016-08-10 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1753147, encodeId=17761e5314740, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Jun 25 10:03:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814766, encodeId=333c1814e6676, content=<a href='/topic/show?id=479d96059ae' target=_blank style='color:#2F92EE;'>#重要分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96059, encryptionId=479d96059ae, topicName=重要分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Apr 15 23:03:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959713, encodeId=e7621959e13b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 10 03:03:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030720, encodeId=854e2030e20af, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Mar 03 23:03:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869455, encodeId=1d841869455db, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 13 00:03:00 CST 2017, time=2017-01-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1753147, encodeId=17761e5314740, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Jun 25 10:03:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814766, encodeId=333c1814e6676, content=<a href='/topic/show?id=479d96059ae' target=_blank style='color:#2F92EE;'>#重要分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96059, encryptionId=479d96059ae, topicName=重要分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Apr 15 23:03:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959713, encodeId=e7621959e13b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 10 03:03:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030720, encodeId=854e2030e20af, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Mar 03 23:03:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869455, encodeId=1d841869455db, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 13 00:03:00 CST 2017, time=2017-01-13, status=1, ipAttribution=)]

相关资讯

CA Cancer J Clin:美国肿瘤幸存者人数逐年增加

近年来男性和女性的癌症发病率稳步下降,癌症幸存者的数量逐年增加。主要原因包括早期发现和治疗方式有效,此外还包括生活质量的提高使得人们寿命更长和人口基数增加。 研究人员指出,尽管人们对生命的认识程度得以提高,但是民众仍然面临许多严峻的挑战。该研究旨在分析当前癌症幸存者的数量和预测水平,研究结果发表在CA: A Cancer Journal for Clinicians。2016年常见癌症男性幸存者人

施贵宝Opdivo PK 默沙东Keytruda,肺癌市场谁胜出?

抗肿瘤免疫疗法当下最大的赢家无疑是免疫哨卡抑制剂,其中最耀眼的产品当属施贵宝的Opdivo和默沙东的Keytruda。虽然Keytruda通过一个超大型一期临床试验得以成功“弯道超车”,提前3个月在美国上市,成为FDA批准的首个PD-1抑制剂。但施贵宝稳扎稳打,在美国市场起步落后的情况下,2015年依然以21亿美元的销售额遥遥领先Keytruda(21 亿美元相比5.66亿美元),而且今年

肺癌早期诊断方法大汇总

肺癌起病隐匿,早期诊断非常重要。临床上常用病理学检查、痰液细胞学检查、X线胸片、胸部CT、血清肿瘤标志物、分子诊断等诊断方法。肺癌的病理学诊断“金标准”1.经皮穿刺肺活检(PALB)从肺部球形病灶直接用穿刺针吸取标本行病理学检查,是目前肺癌诊断最为可靠的手段,它不但能明确诊断,还能进行肺癌病理学分型,据此,临床医师可为患者选定科学合理的治疗方案。但在实际工作中,由于肺癌在胸腔内,部位特殊,肺部

央视|牟巨伟教授:肺癌离我们有多远?

原发性肺癌(以下简称肺癌)是我国最常见的恶性肿瘤之一。国家癌症中心2015年发布的数据显示,2006年-2011年我国肺癌5年患病率是130.2(1/10万)。其中男性84.6(1/10万),居恶性肿瘤第2位。女性45.6 1/10万),居恶性肿瘤第4位。 报告提出,吸烟与将近1/4的国人癌症死亡相关,2010年超过半数的成年男性是当前吸烟者,青少年男性中吸烟率还在攀升。即使这种吸烟率保

Cancer:长达39年的肺癌脑转移差异研究(基于SEER数据)

根据一项发表在Cancer的观察性研究结果称,不同特点(如性别、年龄、组织学等)的非转移性肺癌患者的脑转移发生率不同。在非小细胞肺癌(NSCLC)患者中,脑转移瘤与更差的生存率相关,但小细胞肺癌(SCLC)患者的生存率无关。 底特律韦恩州立大学Karmanos癌症研究所肿瘤科的胸部肿瘤学家Shirish M. Gadgeel博士和同事对1973-2011年的≥20岁的34681例原发性肺癌患

J Periodontol:荟萃分析表明牙周病可增加肺癌的发生风险

既往研究已经表明牙周病与许多系统性疾病(如心血管疾病和糖尿病)有关。而近期的研究又表明,牙周疾病或与肺癌的发生有关。但是,目前尚未确定二者之间确切的关联。因此,本研究旨通过荟萃分析探究牙周疾病与肺癌发生风险之间的关联。研究人员检索了2015年6月10日之前发表在PubMed、Scopus及ScienceDirect上的相关文章。包括探究牙周病患者肺癌发生风险的队列研究和病例对照研究。使用固定效应逆